Roche’s Soliris rival Enspryng bags FDA approval

This post was originally published on this site

Roche’s neuromyelitis optica spectrum disorder (NMOSD) drug Enspryng has scored US Food and Drug Administration (FDA) approval, setting up a market clash with Alexion’s Soliris. Enspryng (satralizumab) has been approved to treat adult patients living …

Click here to read full article